Besides, in the work of Bao et al., DC-tumor hybrid cell-derived chimeric exosomes loaded with STING agonists (DT-Exo-STING) were engineered to address the challenge of balancing antigen-enriched delivery and optimal antigen-presentation functionality in DCs (126). Here, STING1 is linked to neoplasm.